ALEMBICLTD · Alembic Ltd · Biotechnology & Drugs
ALEMBICLTD · Alembic Ltd · Biotechnology & Drugs
As of 06 Nov close
52-week range
14.0% below 52-week high
52-week range: as of 06 Nov 2026 close.
Price chartDaily closes on the stock page.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 16 Oct 2026
Revenue (latest Q)
₹49 Cr
Revenue YoY
PAT YoY
+5.3%
Operating margin
Revenue, last 8 quarters
P/E (TTM)
P/B
1
P/S (TTM)
10.3
Sector P/E
14.1
Dividend yield
+2.5%
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| ALEMBICLTD (this stock) | 7.3 | 1 | +134.2% | +13.1% | 0 | +2.5% |
| Sun Pharmaceutical Industries | 38.4 | 5.6 | +19.1% | +14.2% | 0.47 | +0.8% |
| Divi's Laboratories | 59.7 | 14.5 | +26.1% | +17.4% | 0 | +0.3% |
| Torrent Pharmaceuticals | 72.7 | 19.2 | +15.3% | +27.1% | 141.16 | +0.8% |
Promoter
stable
FII
stable
MF
3.36% (-0.53pp)
falling 1q
Insider trades
| Date | Insider | Type | Qty | Value |
|---|---|---|---|---|
| 30 Sept 2026 | Nirayu Private Limited | BUY | 1,20,155 | ₹1.3 Cr |
| 29 Sept 2026 | Nirayu Private Limited | BUY | 74,554 | ₹79.75 lakh |
| 24 Sept 2026 | Nirayu Private Limited | BUY | 1,67,734 | ₹1.78 Cr |
| 16 Sept 2026 | Nirayu Private Limited | BUY | 1,20,609 | ₹1.22 Cr |
| 02 Sept 2026 | Nirayu Private Limited | BUY | 9,495 | ₹9.41 lakh |
| 01 Sept 2026 | Nirayu Private Limited | BUY | 2,16,969 | ₹2.15 Cr |
| 25 Aug 2026 | Nirayu Private Limited | BUY | 1,29,136 | ₹1.23 Cr |
| 17 Aug 2026 | Nirayu Private Limited | BUY | 4,54,376 | ₹3.99 Cr |
Bulk/block deals
| date | canonicalSymbol | buy quantity | buyer count | deal strength | deal types present |
|---|---|---|---|---|---|
| 2026-09-03 | ALEMBICLTD | 3312628 | 2 | WEAK | BULK |
News timeline
- lowthehindu.com· 05 Nov 2026, 04:50 pmAlembic Pharma Q2 net surges 81% to ₹335 crore
Concalls & investor presentations
AI-generatedNo concall transcripts or investor presentations recorded yet.
AI Summary of Annual Report
AI-generatedAlembic Limited reported a qualified opinion on its consolidated financial statements for FY2023-24 due to a prior year audit qualification related to the transfer of funds from the General Reserve to the Statement of Profit and Loss. The company faces significant challenges in its bulk drugs business, including limited molecules, declining prices, and reduced sales volumes, which threaten its sustainability. The real estate segment showed growth, but the company's overall financial performance details are not provided. No major regulatory actions or defaults were noted, and the auditor's report did not contain adverse remarks on standalone financials.
- Qualified opinion on consolidated financial statements due to prior year audit issue regarding fund transfer from General Reserve.
- Bulk drugs business faces sustainability challenges due to limited molecules, declining prices, and low-margin job-work sales.
- Real estate segment showed growth, but no financial performance figures provided.
- No defaults, regulatory penalties, or adverse audit remarks on standalone financials noted.
Key takeaway: Alembic Limited's consolidated financial statements carry a qualified opinion due to prior year accounting treatment, while its bulk drugs business faces significant sustainability risks, though no immediate defaults or regulatory issues were reported.
The following annual report excerpts provide qualitative strategic context. Do not treat any specific financial figures in these excerpts as authoritative — they may be incorrectly labeled due to PDF table extraction limitations. For precise financial data, refer to the structured fundamentals data above.
Governance disclosures
AI-generatedNeeds attention
Auditor Qualification (3 items)
Items of these kinds are disclosed in the filings. This is a count of disclosed items. It is not a finding about the company and its cause has not been independently established.
Auditor Qualification
3 occurrencesEarlier (1-3 years ago)
The auditor's report for the financial year 2023-24 contains a qualified opinion.
The auditor's report on the consolidated financial statements for the financial year 2022-23 was issued with a qualified opinion due to an audit qualification in the auditor's report of the company's associate entity.
Older (3+ years ago)
The auditor mentions that they did not audit the financial statements of a subsidiary company with total assets of ₹6,471.84 Lakhs as at 31st March 2022, and the consolidated financial statements include the group's share of total comprehensive income of ₹13,626.26 Lakhs from an associate whose financial statements were not audited by them.
Routine disclosures
Contingent Liability
4 occurrencesRecent (last 12 months)
The company has several litigations and contingent liabilities involving significant management judgment and estimates on possible outcomes.
Earlier (1-3 years ago)
The company has a contingent liability related to a disputed electricity duty matter with the State of Gujarat, Collector of Electricity Duty & others, with a principal amount of ₹2,052.13 lakhs and an undetermined interest amount. The company deposited ₹3,500 lakhs with the Hon’ble Supreme Court on 26th May, 2023.
The company has a contingent liability related to a pending electricity duty matter, with a provision of Rs. 2,052.13 lakhs for principal and an undisclosed amount for interest. The company has filed an appeal to the Supreme Court against a dismissed Gujarat High Court order.
Older (3+ years ago)
ALEMBIC LIMITED has contingent liabilities related to wage revision and reinstatement of employees and others as of 31st March, 2022.
Related-Party Transaction
4 occurrencesRecent (last 12 months)
The company engaged in transactions with related parties, including Nirayu Private Limited, Alembic Pharmaceuticals Limited, and Key Managerial Personnel and their relatives, involving rent income, dividend paid, purchase and sale of goods, rendering of services, and reimbursement of expenses during the year ended 31st March, 2026.
Earlier (1-3 years ago)
The company engaged in transactions with related parties, including holding companies, associates, and key managerial personnel and their relatives, involving rent income, dividend paid, security deposit received, purchase and sale of goods, rendering of services, reimbursement of expenses, and managerial remuneration.
The company approved material related party transactions with Shreno Limited, including buying/selling/leasing immovable property, transfer of development rights, and joint development agreements.
Older (3+ years ago)
The company has entered into transactions with Shreno Limited, a related party, which may exceed 10% of its annual consolidated turnover, requiring member approval as per SEBI regulations.
Statutory dues in dispute
3 occurrencesEarlier (1-3 years ago)
Alembic Limited has outstanding statutory dues under the Central Sales Tax Act and Service Tax, with amounts totaling INR 80,16,782, INR 14,42,264, INR 17,30,797, and INR 63,739,636, pending in various forums including Joint commissioner Appeals and Supreme Court.
The company has outstanding statutory dues under the Central Sales Tax Act and Service Tax Act, with amounts totaling Rs. 80,16,782, Rs. 14,42,264, Rs. 17,30,797, and Rs. 6,37,39,636, respectively, with disputes pending in various forums.
Older (3+ years ago)
The company has outstanding statutory dues under the Central Sales Tax Act and Central Excise Act, with amounts totaling 1,28,87,686 as of March 31, 2022, with disputes pending before various forums.
Promoter Share Pledge
1 occurrenceRecent (last 12 months)
2.82% of promoter holding pledged (quarter 2026-Q3 as of 2026-07-18).